A recent study by Kaplan et al indicated that ER+BRCA1-related breast cancers are indistinguishable from ER−BRCA1-related cancers in their nuclear expression of PARP-1, suggesting that ER+BRCA1-related breast cancers may respond well to drugs that exploit BRCA1 deficiency (15). The gene discussed is PARP1; the disease is cancer.